Document is current
Any future updates will be listed below
-
Authors
del Hoyo Soriano, Laura https://orcid.org/0000-0003-4372-1599
Sterling, Audra
Edgin, Jamie
Hamilton, Debra R.
Berry-Kravis, Elizabeth
Dimachkie Nunnally, Amanda
Thurman, Angela John
Abbeduto, Leonard
-
Funding
Funding for this research was provided by:
National Institute of Health (R01HD074346)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD103526)
National Center for Advancing Translational Sciences (UL1TR001860)
- License Information
-
More Information
Article History
Accepted: 28 September 2022
First Online: 31 October 2022
Declarations
:
: EBK has received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Healx, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO, Yamo, Ionis, GeneTx, Acadia, Neurogene, Orphazyme, Ultragenyx, Taysha, Tetra, and Vtesse/ Sucampo/Mallinkcrodt Pharmaceuticals to consult on trial design or development strategies and/or conduct clinical trials in FXS or other genetic neurodevelopmental or neurodegenerative disorders, and from Asuragen Inc. to develop testing standards for FMR1 testing. AJT has received funding from Fulcrum Therapeutics to develop outcome measures for FXS. The other authors declare that they have no competing interests.
